tbuckley/cabot-search huggingface dataset:
Renoprival Hemolysis and Its Prevention by Renal Tissue
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychophysical Methods for the Measurement of Somatosensory Dysfunction in Laboratory Animals
Authors: Patrick A. Cabe
Journal: Environmental Health Perspectives (1982)

Somatosenscry dysfunction is a widely reported clinical consequence of chemical exposure.Assessment of such dysfunction should be an important component of agent safety testing, necessarily implying evaluation of psychophysical functions in laboratory animals.The logic of testing agent-induced sensory dysfunction, conceptual and practical factors affecting such tests, and the categories of experimental methods available are reviewed.
Correction to: Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy
Authors: Seyedeh Maryam Alavi Naini, Constantin Yanicostas, Rahma Hassan-Abdi, Sébastien Blondeel, Mohamed Bennis, Ryan J. Weiss, Yitzhak Tor, Jeffrey D. Esko, Nadia Soussi-Yanicostas
Journal: Translational Neurodegeneration (2020)

An amendment to this paper has been published and can be accessed via the original article.
The State of the Art
Authors: Alvan R. Feinstein
Journal: JAMA (1986)

Her chief complaint is that she wants to die and that the doctors will not let her. She is 96 years old. She has attended the burial of her husband, two daughters-in-law, and all the people who were close friends throughout her lifetime. A woman of fierce and independent spirit, she never wanted to live with her children, to be supported by them, or to be what she calls "a burden." After being widowed 24 years ago, she achieved those goals for a long time because she was in good health and her modest fiscal needs were met by the interest of the trust fund left by her husband. Until 11 years ago, she lived alone and maintained her own apartment. She spent her time walking, talking with neighbors, reading, watching television, playing card games, attending religious services, and traveling to visit children, grandchildren, and great-grandchildren in different cities. At
Lipidomics profiling reveals a distinct pattern of selective lipid depletion in the circulation and liver tissue in patients with progressive alcohol-associated liver fibrosis: a biopsy-controlled study in 400 people
Authors: Maja Thiele, Kajetan Trost, Tommi Suvitaival, Min Kim, Maria Kjærgaard, Suganya Jacobsen, Ditlev Nytoft Rasmussen, Lili Niu, Philipp Geyer, Suguru Nishijima, Helene Bæk Juel, Trine Nielsen, Linda Sevelsted Moeller, Bjørn Stæhr Madsen, Katrine Prier Lindvig, Mads Israelsen, Manimozhiyan Arumugam, Michael Kuhn, Jonel Trebicka, Peer Bork, Torben Hansen, Cristina Legido-Quigly, Aleksander Krag
Journal: Journal of Hepatology (2020)
Oncology
Authors: M. Rothenberg
Journal: JAMA (1990)

Over the past few years, advances have been made in the prevention, detection, and treatment of many of the most common cancers. Some of these advances have direct clinical application and are expected to save or lengthen the lives of thousands of patients with cancer each year. Important achievements have been made in the laboratory as well, where scientists have gained valuable insight into the molecular and genetic events that cause malignant transformation of normal cells. It is likely that the practice of oncology in the 1990s will incorporate much of this knowledge into the optimal treatment of patients with cancer. Colon cancer strikes about 110 000 individuals per year in the United States.<sup>1</sup>Of these, approximately 21000 have tumor that involves regional lymph nodes (ie, Dukes' stage C) at the time of diagnosis. Although all visible tumor may be removed by surgery, 50% to 60% of individuals with
Is Institute of Medicine the agency to lead science's attack on AIDS?
Authors: C. Marwick
Journal: JAMA (1987)

KNOWLEDGE of the acquired immunodeficiency syndrome (AIDS) virus (human immunodeficiency virus [HIV]), its structure, and the way it replicates is now sufficient for development of drugs to prevent or inhibit HIV replication and prevent infection in high-risk groups. At the same time, a national effort is needed to bring government, academia, and industry together to accomplish this. This was the main message from a two-day meeting held by the Institute of Medicine (IOM), Washington, DC, and devoted to discussion of drugs against AIDS. Information accumulated about HIV indicates there are a variety of targets for antiviral drugs, each of which is worthy of a large research effort, notes William Haseltine, MD, Dana-Farber Cancer Center, Boston. Nevertheless, he adds, "The development of anti-HIV drugs is not going to be simply a matter of applying this knowledge. A large segment of this problem lies in the unknown." "There are surprises in store,
TRAUMATIC ASPHYXIA
Authors: A. H. Traver
Journal: JAMA (1923)

C. V. M., aged 47, a farmer, who had always been in good health, was driving his automobile, weighing about 3,000 pounds, over a farm road, Aug. 7, 1922, when the car skidded and went over a bank of about 8 feet. The car tipped entirely over, resting on top of its body, with the wheels in the air. The patient was caught under the overturned car, his back on the ground and the top of the body of the car resting on the lower part of his chest. It was about twenty minutes before the car was jacked up and the patient taken out. The men who saw him thought he was dead, as his face was black. He was able to speak, and seemed conscious, but could not see. He was taken to his home, and I was called. I reached his home at 5: 30 p. m.,
The Utility of Therapeutic Plasmapheresis for Neurological Disorders
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
STEM-08. PLATELETS DRIVES GLIOBLASTOMA ONCOGENESIS BY ENHANCING THE GLIOMA STEM CELL PHENOTYPE
Authors: Anthony Sloan, Christine Lee-Poturalski, Theresa Elder, Peggy Harris, Amber Kerstetter-Fogle, Gino Cioffi, Alankrita Raghavan, John Willis, Jeremy Rich, Jill S Barnholtz-Sloan, Eckhard Jankowsky, Andrew E Sloan
Journal: Neuro-Oncology (2020)

Abstract Glioblastoma (GBM) is recognized as one of the deadliest forms of cancer, despite aggressive therapy consisting of maximal surgical resection followed by concurrent radiation and chemotherapy, the median survival remains ~15 months. Glioma stem cells (GSCs) possess potent tumor-initiating properties and comprise a cellular hierarchy that is responsible for treatment resistance and progression. Specifically targeting GSCs has been considered a promising therapeutic approach, however no clear method has been identified. Histologically, it is known that GSCs are found in perivascular and pseudsopalisading regions of GBM. Similarly, platelet aggregates are often found in pseudsopalisading necrotic regions, suggesting a potential interaction between platelets and GSCs due to their spatial locations. High platelet counts have been associated with poor clinical outcome in many cancers including ovarian and endometrial cancer. While platelets are known to affect progression of other tumors, mechanisms by which platelets influence GBM oncogenesis are unknown. Our work aimed to understand the crosstalk between GSCs and platelets within GBM solid tumors that work to enhance disease progression and treatment resistance. Our clinical studies suggest elevated platelet counts positively correlate with tumor growth and negatively correlate to overall patient survival. We found platelets and GSC co-localization in GBM solid tissue; platelet exposure to GSCs results in increased proliferation of GSCs specifically, by increasing the self-renewing capacity of GSCs in a dose dependent manner, and resulted in an increased “Stem-like” transcriptional pattern. Consequently, inhibiting the GSC-platelet interaction results in a decrease in GSC renewal and stemness. These results introduce a novel interaction between GSCs and platelets and elucidate a novel therapeutic approach specifically targeting GSCs by disrupting the GSC-platelet interaction.
Plastic Surgery
Authors: Bradford Cannon
Journal: JAMA (1980)

The format of this book, one of the<i>Operative Surgery</i>series, is reminiscent of other British publications, with a brief descriptive text immediately adjacent to the serial illustrations. The list of contributors reads like a worldwide<i>Who's Who</i>in plastic surgery, giving an international flavor to the techniques described. There is an abundance of line drawings or half-tones to illustrate each step in the procedures chosen. Almost every aspect of reconstructive surgery is included, from facial clefts to hypospadias, from wound repair to pressure sores, and from skin grafts to sophisticated flaps. With rare exceptions the statements in the text are dogmatic with little discussion of the principles involved: "The sutures are removed on the 5th day"; "The area is cleaned with Savlon"; "dressings with gauze wrung out with Eusol"; "Make the defect fit the flap and not the flap the defect" (p 44)—strange statement! Several doubtful conclusions would concern
Tears
Authors: Paula S. Krauser
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgical Treatment of High Pressure Patent Ductus Arteriosus
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The crisis in primary care and the role of medical schools. Defining the issues
Authors: B. Stimmel
Journal: JAMA (1992)

THE HEALTH care theme of the mid-1960s was insufficient physician supply, and the need to increase medical school enrollment was endorsed by many. Both federal and state legislators provided considerable financial incentives to schools to increase their enrollments and to prospective medical students to defray the costs of their medical education through low-interest loans. As a result, new first-year enrollments at US medical schools rose from 8483 in 1961 to 16103 in 1986 and have been maintained essentially at this level, with only a slight decrease in 1990 to 15998.<sup>1</sup> In 1980, the publication of the Summary Report of the Graduate Medical Education National Advisory Committee raised for the first time the question of whether, with the exception of primary care physicians, we were training far more physicians than were needed.<sup>2</sup>A future "physician glut" became commonly assumed. Over the last several years, the accuracy of this prediction
Table Copyrighted.
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liver transplantation and alcohol: Who should get transplants?
Authors: Ruud A. F. Krom
Journal: Hepatology (1994)

Medical selection criteria should be the same for all patients with end-stage liver disease and should aim for an acceptable outcome of the liver transplant procedure in matter of survival and quality of life, taking the scarce resources into account. The psychiatric selection criteria should aim at avoidance of recidivism of alcohol use in alcoholic patients. At least 6 mo of sobriety should be required. The patient must have a stable and supportive environment and should participate in an alcohol counseling program. A multicentered trial using uniform scoring criteria such as the Alcohol Prognosis Scale is needed to better define the selection of patients with alcoholic liver disease and long-term outcome of alcoholism after transplantation. (Hepatology 1994;20:28S-32S.)
IMPROVED ATOMIZER.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
WAR CORRESPONDENCE.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT
Authors: Christian Koenecke, Gudrun Göhring, Liesbeth de Wreede, Anja van Biezen, Christof Scheid, Liisa Volin, Johan Maertens, Juergen Finke, Nicolaas PM Schaap, Marie Robin, Jakob R. Passweg, Jan J Cornelissen, Dietrich Beelen, Michael Heuser, Theo de Witte, Nicolaus Kröger
Journal: Blood (2013)
EXTH-28. ENHANCING SELUMETINIB-MEDIATED KILLING OF SHH MEDULLOBLASTOMA
Authors: Brent Guppy, Lisa Liang, Chris Porter, Tamra Werbowetski-Ogilvie
Journal: Neuro-Oncology (2018)

Medulloblastoma (MB) is the most common primary malignant pediatric brain cancer and consists of at least 5 distinct molecular subgroups. Of these subgroups, Sonic Hedgehog (SHH) MB exhibits extensive cellular heterogeneity, increased SHH signaling, and has an intermediate prognosis. Treatment strategies employing SHH pathway inhibitors showed initial promise, however, acquired drug resistance has led to therapy failure in clinical trials. Consequently, improved chemotherapeutic strategies designed to better treat SHH MB must be identified. A major contributing factor to cellular heterogeneity, and thus drug resistance and disease progression, are rare putative brain tumor-propagating cells (TPC). As a result, identifying robust TPC biomarkers can reveal novel subgroup-specific therapies capable of targeting these elusive cell types. We recently identified the neurotrophin receptor (CD271) within the SHH MB subgroup as a promising biomarker delineating TPC populations and associated with elevated MEK/ERK signaling. Moreover, we showed that selumetinib, a MEK inhibitor, reduced CD271 levels, decreased TPC growth, and extended survival in mouse models. While promising, the mice in our in vivo studies ultimately succumb to disease progression; thus, an enhanced selumetinib-based chemotherapeutic strategy is merited. In this study, we employed RNA-sequencing to identify 543 genes differentially expressed in selumetinib resistant xenografts relative to controls. Further, gene set enrichment analysis revealed significant changes in specific signaling pathways predicted to underlie selumetinib resistance and contribute to SHH MB progression. Accordingly, to ultimately enhance survival, we employ our high-content tumorsphere assay to systematically evaluate candidate blood brain penetrant inhibitors that are highly predicted to elicit therapeutic synergy in combination with selumetinib in vivo. In addition, we will test selumetinib in combination with current SHH MB standard of care chemotherapeutics to characterize survival. Our studies will reveal mechanisms of SHH MB drug resistance, and identify novel drug combinations that may ultimately enhance MB patients’ survival and quality of life.
Retraction: “The Role of the Extracellular Matrix Protein Mindin in Airway Response to Environmental Airways Injury”
Authors: Sarah Frush, Zhuowei Li, Erin N. Potts, Wanglei Du, Jerry P. Eu, Stavros Garantziotis, You-Wen He, W. Michael Foster, John W. Hollingsworth
Journal: Environmental Health Perspectives (2016)
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)
Authors: Andrew J. Yee, William Bensinger, Peter M. Voorhees, Jesus G. Berdeja, Paul G. Richardson, Jeffrey Supko, David Tamang, Simon S Jones, Catherine Wheeler, Robert J Markelewicz, Noopur S. Raje
Journal: Blood (2015)